Robert Hershberg
Chief Executive Officer at HILLEVAX, INC.
Net worth: 10 M $ as of 2024-04-29
Profile
Robert M.
Hershberg is the founder of VentiRx Pharmaceuticals, Inc. (founded in 2006) and HilleVax, Inc. (founded in 2020).
He held the title of President, Chief Executive Officer & Director at VentiRx Pharmaceuticals, Inc. from 2012 to 2017.
Currently, he is the Chairman, President & Chief Executive Officer at HilleVax, Inc. (founded in 2020).
In his current roles, Dr. Hershberg is an Independent Director at Recursion Pharmaceuticals, Inc. (since 2020), Fate Therapeutics, Inc. (since 2020), and Adaptive Biotechnologies Corp.
(since 2013).
He is also a Director at Cajal Neuroscience, Inc. and a Member at UW Medicine.
Previously, Dr. Hershberg served as an Independent Director at NanoString Technologies, Inc. from 2015 to 2022.
He was also an Independent Director at Silverback Therapeutics, Inc., a Director at Guide Therapeutics, Inc., and the Chief Scientific Officer & Executive VP at Celgene Corp.
from 2016 to 2019.
Additionally, he held the position of Vice President-Medical Genetics at Corixa Corp.
from 2001 to 2003 and Chief Medical Officer & Senior Vice President at Dendreon Corp.
from 2003 to 2006.
He was an Assistant Professor at Harvard Medical School.
Dr. Hershberg obtained his doctorate degree from The Salk Institute for Biological Studies in 1992.
He also holds undergraduate and doctorate degrees from the University of California, Los Angeles.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
HILLEVAX, INC
1.64% | 2024-03-31 | 812,856 ( 1.64% ) | 10 M $ | 2024-04-29 |
| 2024-04-11 | 38,619 ( 0.02% ) | 302 773 $ | 2024-04-29 | |
| 2024-03-31 | 75,968 ( 0.05% ) | 198 276 $ | 2024-04-29 | |
FATE THERAPEUTICS, INC.
0.01% | 2024-03-30 | 10,659 ( 0.01% ) | 41 250 $ | 2024-04-29 |
Robert Hershberg active positions
| Companies | Position | Start |
|---|---|---|
| ADAPTIVE BIOTECHNOLOGIES CORPORATION | Director/Board Member | 2013-01-31 |
| RECURSION PHARMACEUTICALS, INC. | Director/Board Member | 2020-03-19 |
| FATE THERAPEUTICS, INC. | Director/Board Member | 2020-04-30 |
| HILLEVAX, INC. | Chief Executive Officer | 2020-03-24 |
| UW Medicine | Corporate Officer/Principal | - |
Cajal Neuroscience, Inc.
 Cajal Neuroscience, Inc. BiotechnologyHealth Technology Cajal Neuroscience is a biotechnology company that focuses on discovering new treatments for neurodegeneration. The company is based in Seattle, WA and was founded by Ian Peikon. The company uses advanced technologies such as integrative human genetics, multi-omics, functional genomics, and microscopy to accelerate their target and drug discovery. | Director/Board Member | - |
Former positions of Robert Hershberg
| Companies | Position | End |
|---|---|---|
| NANOSTRING TECHNOLOGIES, INC. | Director/Board Member | 2022-04-17 |
| CELGENE | Chief Tech/Sci/R&D Officer | 2018-12-31 |
VentiRx Pharmaceuticals, Inc.
 VentiRx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology VentiRx Pharmaceuticals, Inc. develops and commercializes novel medicines for the treatment of cancer, respiratory, and inflammatory diseases. It focuses on the development of novel small molecule product candidates targeting toll-like receptor 8 for applications in oncology, allergy, autoimmune, and inflammatory diseases. The company was founded by Michael J. Kamdar and Robert Hershberg on June 12, 2006 and is headquartered in Seattle, WA. | Chief Executive Officer | 2017-02-28 |
| ░░░░░░░░ ░░░░░░░░░░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Training of Robert Hershberg
| The Salk Institute for Biological Studies | Doctorate Degree |
| University of California, Los Angeles | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 5 |
|---|---|
| RECURSION PHARMACEUTICALS, INC. | Health Technology |
| NANOSTRING TECHNOLOGIES, INC. | Health Technology |
| FATE THERAPEUTICS, INC. | Health Technology |
| ADAPTIVE BIOTECHNOLOGIES CORPORATION | Health Technology |
| HILLEVAX, INC. | Health Technology |
| Private companies | 7 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
Corixa Corp.
 Corixa Corp. BiotechnologyHealth Technology Corixa Corp. operates as a biopharmaceutical company. It develops and manufactures oncology and immunology products. The firm offers vaccines, immunotherapeutic, monoclonal antibody-based therapeutics, adjuvant and antigen delivery systems, toxin-conjugated, and antigen-specific diagnostic products. The company was founded by Steven H. Gillis and Mark McDade in 1994 and is headquartered in Hamilton, MT. | Health Technology |
Dendreon Corp.
 Dendreon Corp. Medical SpecialtiesHealth Technology Dendreon Corp. discovers, develops and commercializes novel products for the treatment of cancer. The company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy ACI product candidates designed to stimulate an immune response in a variety of tumor types. It is an exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. Dendreon was founded by Christopher S. Henney, Edgar G. Engleman and Samuel Strober in 1992 and is headquartered in Seattle, WA. | Health Technology |
VentiRx Pharmaceuticals, Inc.
VentiRx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology VentiRx Pharmaceuticals, Inc. develops and commercializes novel medicines for the treatment of cancer, respiratory, and inflammatory diseases. It focuses on the development of novel small molecule product candidates targeting toll-like receptor 8 for applications in oncology, allergy, autoimmune, and inflammatory diseases. The company was founded by Michael J. Kamdar and Robert Hershberg on June 12, 2006 and is headquartered in Seattle, WA. | Health Technology |
Silverback Therapeutics, Inc.
 Silverback Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Silverback Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. The company was founded by Peter A. Thompson January 4, 2016 and is headquartered in Seattle, WA. | Health Technology |
Guide Therapeutics, Inc.
 Guide Therapeutics, Inc. BiotechnologyHealth Technology Guide Therapeutics, Inc. develops biophotonic technology platform for the early detection of disease that leads to cancer. The company was founded by James Dahlman and Cory Sago and is headquartered in Tucker, GA. | Health Technology |
Cajal Neuroscience, Inc.
Cajal Neuroscience, Inc. BiotechnologyHealth Technology Cajal Neuroscience is a biotechnology company that focuses on discovering new treatments for neurodegeneration. The company is based in Seattle, WA and was founded by Ian Peikon. The company uses advanced technologies such as integrative human genetics, multi-omics, functional genomics, and microscopy to accelerate their target and drug discovery. | Health Technology |
- Stock Market
- Insiders
- Robert Hershberg
